Report library

Liquid Biopsy Oncology Market

This comprehensive medical market and technology report provides an overview and in-depth market analysis of liquid biopsy products used in the field of oncology. In 2020, the global market for liquid biopsy products for oncology applications was valued at approximately $1.9bn.

October 11, 2021

Disease Analysis: Diffuse Large B-Cell Lymphoma (DLBCL)

Interventional Cardiology: Carotid Artery Stents and Embolic Protection Systems

This medical market and technology report provides a comprehensive discussion of the global market for carotid artery stents and embolic protection systems. Geographically

September 9, 2021

Follicular Lymphoma KOL Interview – UK

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for follicular lymphoma. Disease stratification by staging and expression as well as unmet needs are also discussed. Key assets highlighted include Rituxan, Revlimid, Gazyva, Yescarta, Imbruvica, Kymriah, Tazverik, and mosunetuzumab.

June 11, 2021

Transcatheter Heart Valve Repair and Replacement Devices

In 2020, the global market for transcatheter heart valve management products, including transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve (TMV) repair products, totaled nearly $4.7bn, with TAVR products accounting for nearly 90% of sales.

August 30, 2021

Q3 2021 Outlook Report

In this report, we cover catalysts from 27 drugs, devices, diagnostics, and deals expected to occur in the third quarter of 2021. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Informa’s drug development benchmarking product utilizing Biomedtracker’s LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker.

June 2, 2021

HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #2

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HIV PrEP. Drug pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include islatravir and cabotegravir.

August 10, 2021

HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #1

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HIV PrEP. Drug pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include islatravir and cabotegravir.

August 10, 2021

Chronic Myeloid Leukemia (CML) KOL Interview – US, Midwest

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for chronic myeloid leukemia. Disease stratifications by phase, as well as unmet needs, are also discussed. Key pipeline assets highlighted include asciminib, SCO-088, and ASTX030.

August 5, 2021

Chronic Myeloid Leukemia (CML) KOL Interview – UK

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase as well as exploratory mid-phase pipeline therapies for chronic myeloid leukemia. Key pipeline assets highlighted include vodobatinib and Dasynoc.

July 8, 2022

Fracture Fixation Devices Market

This medical market and technology report provides a comprehensive discussion of the global market for fracture fixation devices.

August 5, 2021

Follicular Lymphoma KOL Interview – US

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for follicular lymphoma. Disease stratification by staging and expression, as well as unmet needs, are also discussed. Key assets highlighted include Rituxan, Revlimid, Gazyva, Yescarta, Imbruvica, Kymriah, and mosunetuzumab.

July 16, 2021

Point of Care Diagnostics

Point of care in vitro diagnostics is being applied to an increasingly wide range of applications in infectious disease, cardiovascular, respiratory, and metabolic disease diagnosis and screening. The market is undergoing rapid expansion, primarily due to the demand for COVID-19 testing; however, other product segments will also contribute to market growth during the forecast period.

June 28, 2021

Surgical Heart Valve Repair and Replacement Devices

This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the surgical heart valve repair (annuloplasty) systems and surgical heart valve replacement products markets for the US, 5 Euro (France, Germany, Italy, Spain, and UK), Japan, and Rest of World markets from 2020–25.

June 28, 2021